How to buy Frequency Therapeutics stock | $8.85

Frequency Therapeutics, Inc is a biotechnology business based in the US. Frequency Therapeutics shares (FREQ) are listed on the NASDAQ and all prices are listed in US Dollars. Frequency Therapeutics employs 83 staff and has a trailing 12-month revenue of around 0.00.

Frequency Therapeutics stock price (NASDAQ: FREQ)

Use our graph to track the performance of FREQ stocks over time.

Frequency Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$8.85
52-week range	$7.34 - $58.37
50-day moving average	$9.33
200-day moving average	$22.51
Wall St. target price	$16.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.64

Buy Frequency Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Frequency Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Frequency Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Frequency Therapeutics price performance over time

Historical closes compared with the close of $8.85 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	-11.23%
3 months (2021-04-29)	-20.77%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Frequency Therapeutics financials

Revenue TTM	$34.4 million
Gross profit TTM	$5 million
Return on assets TTM	-11.51%
Return on equity TTM	-24.53%
Profit margin	-122.12%
Book value	$5.19
Market capitalisation	$269.6 million

TTM: trailing 12 months

Shorting Frequency Therapeutics shares

There are currently 5.5 million Frequency Therapeutics shares held short by investors – that's known as Frequency Therapeutics's "short interest". This figure is 8.6% down from 6.0 million last month.

There are a few different ways that this level of interest in shorting Frequency Therapeutics shares can be evaluated.

Frequency Therapeutics's "short interest ratio" (SIR)

Frequency Therapeutics's "short interest ratio" (SIR) is the quantity of Frequency Therapeutics shares currently shorted divided by the average quantity of Frequency Therapeutics shares traded daily (recently around 537557.22713864). Frequency Therapeutics's SIR currently stands at 10.17. In other words for every 100,000 Frequency Therapeutics shares traded daily on the market, roughly 10170 shares are currently held short.

However Frequency Therapeutics's short interest can also be evaluated against the total number of Frequency Therapeutics shares, or, against the total number of tradable Frequency Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Frequency Therapeutics's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Frequency Therapeutics shares in existence, roughly 160 shares are currently held short) or 0.18% of the tradable shares (for every 100,000 tradable Frequency Therapeutics shares, roughly 180 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Frequency Therapeutics.

Find out more about how you can short Frequency Therapeutics stock.

Frequency Therapeutics share dividends

We're not expecting Frequency Therapeutics to pay a dividend over the next 12 months.

Frequency Therapeutics overview

Frequency Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc.

Frequently asked questions

What percentage of Frequency Therapeutics is owned by insiders or institutions?
Currently 12.329% of Frequency Therapeutics shares are held by insiders and 60.161% by institutions. How many people work for Frequency Therapeutics?
Latest data suggests 83 work at Frequency Therapeutics. When does the fiscal year end for Frequency Therapeutics?
Frequency Therapeutics's fiscal year ends in December. Where is Frequency Therapeutics based?
Frequency Therapeutics's address is: 75 Hayden Avenue, Lexington, MA, United States, 02421 What is Frequency Therapeutics's ISIN number?
Frequency Therapeutics's international securities identification number is: US35803L1089 What is Frequency Therapeutics's CUSIP number?
Frequency Therapeutics's Committee on Uniform Securities Identification Procedures number is: 35803L108